Integra Therapeutics Presented ex vivo and in vivoData for its FiCAT Gene Writing Platform at Advanced Therapies Europe
12 September 2023
Integra Therapeutics presented positive data from ex vivo and in vivo preclinical studies demonstrating the potential of its FiCAT gene writing platform for developing advanced therapies in pediatric hepatology at Advanced Therapies Europe.
“The ex vivo and in vivo preclinical data validates our FiCAT
gene-writing platform for developing cell and gene therapies for patients with
genetic minority and oncological diseases and is driving us to intensify our
efforts to move into the preclinical regulatory phase in the coming months,”
FiCAT has been tested for ex vivo cell engineering and in vivo therapy. Integra Therapeutics continues to expand FiCAT with
tools such as more effective alternative transposons and programmable nucleases
due to it high-performance system to detect improved genome editors and protein
design using artificial intelligence to potentially achieve safer and more
flexible, efficient, and broadly applicable gene writing. The company is
supported by international investors such as AdBio Partner, Columbus Venture
Partners, Invivo Capital and Takeda Ventures. It has also obtained the My Green
Lab sustainability certification in 2023. Source: Integra Therapeutics Press Release</a >
While we have you…
We are continuously working to better optimize our content for you, our
audience. Let us know how we’re doing by ticking the box below, or send us your
feedback directly to email@example.com.
Xavier De Mollerat Du Jeu, Senior Director R&D at Thermo Fisher Scientific is accompanied by Gianluca Pettiti, Executive Vice President and President, Life Sciences Group at Thermo Fisher Scientific and Fred Parietti, Co-Founder and CEO at Multiply Labs for this Workshop at Advanced Therapies Week 2024.
Manufacturing capacity, complexity and cost are core constraints that limit commercialization of cell and gene therapies, and ultimately patient access. In this Fireside Chat series, join Georgi Makin, VP of Digital & Editorial at Phacilitate and the Germfree team as we discuss the challenges and opportunities associated with delivering cell therapies in a decentralized manufacturing model.